Antipodes Partners’s UBS Group UBS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$22.5M Sell
587,054
-303,378
-34% -$13M 0.43% 50
2025
Q4
$41.5M Sell
890,432
-199,422
-18% -$8.06M 0.87% 38
2025
Q3
$44.5M Sell
1,089,854
-1,342,375
-55% -$52.1M 1% 36
2025
Q2
$82M Sell
2,432,229
-252,060
-9% -$7.8M 2.54% 17
2025
Q1
$81.5M Buy
2,684,289
+234,528
+10% +$7.82M 2.55% 18
2024
Q4
$75M Buy
2,449,761
+585,319
+31% +$18.6M 2.61% 16
2024
Q3
$57.6M Buy
+1,864,442
New +$56M 2% 24

Other funds holding UBS

Antipodes Partners's UBS Position: Q1 2026 in Review

Antipodes Partners reduced its UBS Group (UBS) stake by 34% in Q1 2026, selling an estimated $13M and leaving 587,054 shares worth $22.5M. The position accounts for 0.43% of the portfolio, ranked #50.

Antipodes Partners first reported a position in UBS in Q3 2024 and has held it in 7 quarters since. The position peaked at $82M in Q2 2025. 681 funds tracked by Wall St. Rank hold UBS as of Q1 2026.

  • Antipodes Partners held 587,054 shares of UBS Group worth $22.5M as of Q1 2026.
  • Antipodes Partners sold 303,378 UBS Group shares in Q1 2026, an estimated $13M.
  • UBS Group made up 0.43% of Antipodes Partners's portfolio in Q1 2026, its #50 holding.
  • Antipodes Partners first reported a position in UBS Group in Q3 2024 and has held it in 7 quarters since.
  • Antipodes Partners's UBS Group position peaked at $82M in Q2 2025.
  • 681 funds tracked by Wall St. Rank held UBS Group as of Q1 2026.

Based on Antipodes Partners's 13F filing for Q1 2026, filed 5 May 2026.